Donate

Genentech Announces the Launch of New Safety Website

September 3, 2018

Genentech has announced a new web portal for patients and caregivers intended to provide timely and accurate information on targeted serious adverse events of interest for HEMLIBRA. Visit the safety website:聽http://www.emipatientinfo.com/. Earlier this year, Genentech launched a similar site specifically for health care providers. In announcing the launch, Genentech stated 鈥淭his website is meant to […]

Genentech Releases Statement on Hemlibra Patient

April 24, 2018

The following is an excerpt from a statement from Genentech. Read the entire statement 聽HERE. _________________________________________________________ Genentech has recently learned that a patient in the Phase III HAVEN 2 clinical trial developed a neutralizing anti-drug聽antibody. For聽this patient, the anti-drug antibody resulted in reduced efficacy of HEMLIBRA.


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.